Evidence map›Paper›PMID 27766277›Full record

ArticleAmerican journal of clinical and experimental urology2016

Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D

David Jarrard, Badrinath Konety, Wei Huang, Tracy Downs, Jill Kolesar, Kyung Mann Kim, Tom Havighurst, Joel Slaton, Margaret G House, Howard L Parnes and 1 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of clinical and experimental urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Vitamin D Receptor Signaling and Cancer.Endocrinology and metabolism clinics of North America · 2017
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

David JarrardDepartment of Urology, University of Wisconsin School of Medicine and Public HealthMadison, WI, USA; Environmental and Molecular Toxicology, University of WisconsinMadison, WI, USA; University of Wisconsin Carbone Cancer CenterMadison, WI, USA.
Badrinath KonetyDepartment of Urology, University of Minnesota Minneapolis, MN, USA.
Wei HuangDepartment of Pathology and Laboratory Medicine, University of Wisconsin Madison, WI, USA.
Tracy DownsDepartment of Urology, University of Wisconsin School of Medicine and Public HealthMadison, WI, USA; University of Wisconsin Carbone Cancer CenterMadison, WI, USA.
Jill KolesarDepartment of Pathology and Laboratory Medicine, University of WisconsinMadison, WI, USA; University of Wisconsin Carbone Cancer CenterMadison, WI, USA; School of Pharmacy, University of WisconsinMadison, WI, USA.
Kyung Mann KimDepartment of Biostatistics and Medical Informatics, University of WisconsinMadison, WI, USA; University of Wisconsin Carbone Cancer CenterMadison, WI, USA.
Tom HavighurstDepartment of Biostatistics and Medical Informatics, University of WisconsinMadison, WI, USA; University of Wisconsin Carbone Cancer CenterMadison, WI, USA.
Joel SlatonDepartment of Urology, University of Minnesota Minneapolis, MN, USA.
Margaret G HouseNational Cancer Institute Bethesda, MD, USA.
Howard L ParnesNational Cancer Institute Bethesda, MD, USA.
Howard H BaileyDepartment of Medicine, University of Wisconsin School of Medicine and Public HealthMadison, WI, USA; University of Wisconsin Carbone Cancer CenterMadison, WI, USA.
National Cancer Institute · USUniversity of Minnesota · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

objectivesProstate cancer (PCa) represents an important target for chemoprevention given its prolonged natural history and high prevalence. Epidemiologic and laboratory data suggest that vitamin D and genistein (soy isoflavone) may decrease PCa progression. The effect of vitamin D on prostate epithelial cell proliferation and differentiation is well documented and genistein may augment this affect through inhibition of the CYP24 enzyme, which is responsible for intracellular vitamin D metabolism. In addition, both genistein and vitamin D inhibit the intraprostatic synthesis of prostaglandin E2, an important mediator of inflammation. The objectives of this prospective multicenter trial were to compare prostate tissue calcitriol levels and down-stream related biomarkers in men with localized prostate cancer randomized to receive cholecalciferol and genistein versus placebo cholecalciferol and placebo genistein during the pre-prostatectomy period.

methodsMen undergoing radical prostatectomy were randomly assigned to one of two treatment groups: (1) cholecalciferol (vitamin D

resultsA total of 15 patients were enrolled, 8 in the placebo arm and 7 in the vitamin D

conclusionsIn this first study testing the combination of a single, large dose of cholecalciferol and daily genistein, the agents were well tolerated. While an increase in AR expression suggesting differentiation was observed, it is difficult to draw firm conclusions regarding the bioactivity of the combination given the sample size.

Indexed as

active surveillenceCholecalciferolgenesteinprostate cancer

Identifiers

PMID27766277
PMCPMC5069272
OpenAlexW2544443493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.